Facebook
Twitter
LinkedIn
ForwardReal Psychiatry: A Live Virtual Educational Experience Designed for and by Advanced Practice Professionals on the Frontlines of Modern Practice
Program Description
Mental health disorders have surged in recent years, during which the demand for advanced practice professionals (APPs), particularly nurse practitioners (NPs), has increased dramatically. In the midst of this rising need, many NPs have reported a desire for greater education that is designed to meet their needs. To address this, EfficientCME and Partners for Advancing Clinical Education (PACE) present "Real Psychiatry," a comprehensive 6-module series created primarily by and for APPs. Covering topics such as depression (unipolar and bipolar), substance use disorder, ADHD, schizophrenia, antipsychotics, drug-induced movement disorders, and prior authorizations, this program emphasizes hands-on learning and evidence-based clinical implementation to enhance practical psychiatric care.
Target Audience
This activity is intended for advanced practice professionals caring for patients with common psychiatric disorders.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Slide Decks | |
Welcome Address |  Welcome Address_.pdf |
Intersecting Indications: The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management | Intersecting_.pdf |
Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics | Antipsychotics.pdf |
Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs | Road Map.pdf |
The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience | The Real Schizophrenia.pdf |
Turning the Tide in Bipolar Depression | Turning the Tide in Bipolar Depression.pdf |
Extrapyramidal Symptoms: When are They Tardive Dyskinesia? | Extrapyramidal Symptoms.pdf |
The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies | The Changing Face of MDD.pdf |
Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan | ADHD.pdf |
Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment | SUD.pdf |
Closing Remarks | Closing Remarks_.pdf |
Glossary | Brand Names.pdf |
Welcome Address 8:00 am - 8:10 am (10 min)
Intersecting Indications: The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management 8:10 am - 8:55 am (45 min)
Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics 8:55 am - 9:55 am (60 min)
Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs 10:10 am - 10:35 am (25 min)
The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience 10:35 am - 11:25 am (50 min)
Turning the Tide in Bipolar Depression 11:25 am - 12:10 pm (45 min)
Extrapyramidal Symptoms: When are They Tardive Dyskinesia? 1:10 pm - 1:55 pm (45 min)
The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies 1:55 pm - 2:40 pm (45 min)
Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan 2:50 pm - 3:35 pm (45 min)
Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment 3:35 pm - 4:05 pm (30 min)
Closing Remarks 4:05 pm - 4:15 pm (10 min)
Carmen Kosicek, MSN, APNP, PMHNP-BC (Chair)
Ann Barbaro, MSN, APRN, PMHNP-BC
Clinical Professor, Psychiatry and Behavioral Sciences
Bobbi Jo Durst, MSN, APNP, PMHNP- BCPsychiatric Mental Health Nurse Practitioner
Alay Health Team / Delke & Dursahl LLC
Shannon Eaton, MSN, APN, PMHNP-BCMindful Therapy Group
Christina Fuchs, DNP, PMHNP- BC
Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BCPsychiatric-Mental Health Nurse Practitioner
SPGPM2 Services, LLC
Karen J Greene MSN, Ed, APRN, FNP-C, PMHNP-BCOwner
Mountainside Healthcare LLC
Amber Hoberg, MSN, APRN, PMHNP-BCMorningstar Family Medicine / Baptist Health System
Mark Jankelow MSN, BA, PMHNP-BCSpringbok Health, Inc
Mia W. Jones, MSN, APRN, PMHNP-BCPsychiatric Mental Health Nurse Practitioner
Gupta Psychiatry
Tina Matthews-Hayes, DNP, FMP-C, PHMNP-BNurse Practitioner
Seaside Behavioral Health
Chelsea Schwartz, MSN, APRN, PMHNP-BCPsychiatric Mental Health Nurse Practitioner
“Phone a Pharmacist” Faculty
To receive CE credit, please follow these steps:
For Physicians, Nurses, and Others (excluding Psychologists):
- Visit: https://paceducation.com/RealPsychiatry
- Complete the activity evaluation
- Upon completion of all evaluation questions your credit will be made available for download immediately.
For Psychologists:
- Visit: https://paceducation.com/RealPsychiatryAPA
- Select a session attended and complete the activity evaluation
- Upon completion of all evaluation questions your credit will be made available for download immediately.
- To return to the session listing and claim additional credits, click on the above link to return to the homepage.
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.Upon completion of these sessions, psychologist participants should be able to:
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
- Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
- Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
- Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
- Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Faculty and Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
- Consulting Fees: AbbVie, Boehringer Ingelheim, Corium, Eisai, Intra-Cellular, Teva
- Speakers Bureau: AbbVie/Allergan, Alkermes, Intra-Cellular, Teva, US World Meds
Ann Barbaro, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
Leslie Citrome, MD, MPH reported the following relationships:
- Contracted Research: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona
- Consulting Fees: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, and Teva
Bobbi Jo Durst, MSN, APNP, PMHNP- BC has no financial relationships to disclose.
Shannon Eaton, MSN, APN, PMHNP-BC has no financial relationships to disclose.
Christina Fuchs, DNP, PMHNP-BC has no financial relationships to disclose.
Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC has no financial relationships to disclose.
Karen J Greene MSN, Ed, APRN, FNP-C, PMHNP-BC has no financial relationships to disclose.
Amber Hoberg, MSN, APRN, PMHNP-BC reported the following relationships:
- Consulting Fees: Alkermes, Intra-Cellular, Karuna, Neurocrine, Teva
- Spealers Bureau: Acadia, BioXcel, Intra-Cellular, Neurocrine, Otsuka, Teva
Mark Jankelow MSN, BA, PMHNP-BC reported the following relationships:
- Consulting Fees: AbbVie, Alkermes, and Teva
- Speakers Bureau: AbbVie, Alkermes, and Teva
Mia W. Jones, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B reported the following relationships:
- Consulting Fees: AbbVie, Johnson & Johnson, and Teva
- Speakers Bureau: AbbVie, Biogen/Sage, Johnson & Johnson, Neurocrine, and Teva
Chelsea Schwartz, MSN, APRN, PMHNP-BC has no financial relationships to disclose.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Efficient LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Support
This activity is supported by independent educational grants from Indivior Inc., Intra-Cellular Therapies, Inc., Teva Pharmaceuticals, and Tris Pharma, Inc.